If You Invested in Innate Pharma Marseille (IPHYF)
Looking for the current price? See the IPHYF quote & overviewWhat $1,000 or $10,000 in IPHYF Would Be Worth Now
Real historical value by amount invested and how long ago| If you invested | 1 year ago | 5 years ago | 10 years ago | Since Dec 31, 2021 |
|---|---|---|---|---|
| $1,000 | $1,019 +2% | — | — | $379 -62% |
| $10,000 | $10,185 +2% | — | — | $3,793 -62% |
Based on real historical closing prices, dividend- and split-adjusted, through 2026-05-27. Past performance does not guarantee future results.
Custom Calculation
Choose your own date and amount for IPHYF$1,000 Investment Over Time
IPHYF vs S&P 500Year-by-Year Returns
IPHYF annual performance| Year | Start Price | End Price | Annual Return | Cumulative |
|---|---|---|---|---|
| 2021 | $4.35 | $4.35 | +0.0% | +0.0% |
| 2022 | $4.34 | $3.27 | -24.7% | -24.8% |
| 2023 | $3.51 | $2.84 | -19.1% | -34.7% |
| 2024 | $2.52 | $2.90 | +15.1% | -33.3% |
| 2025 | $1.76 | $2.15 | +22.4% | -50.5% |
| 2026 | $1.3725 | $1.65 | +20.2% | -62.1% |
About Innate Pharma Marseille
Healthcare · OTC Link
Innate Pharma S.A. (IPHYF) is identified in regulatory filings as Innate Pharma S.A., a foreign private issuer that reports to the U.S. Securities and Exchange Commission on Form 20-F. The company appears in SEC filings under the name Innate Pharma S.A. and files current reports on Form 6-K as a foreign issuer.
According to its SEC disclosures, Innate Pharma S.A. is based in Marseille, France. Its principal executive office is located in Marseille, and the company provides English and French versions of its name in filings, indicating that it is a French company that also communicates with international investors.
Innate Pharma S.A. files Form 6-K current reports that reference press releases as exhibits. These filings show that the company uses SEC submissions to provide updates to investors and the market, with exhibits labeled as press releases attached to the 6-K reports.
The company’s filings include detailed financial and structural information prepared under IFRS, with references to ordinary shares, preference shares, issued capital, share premium, retained earnings, and accumulated other comprehensive income. The filings also reference various members or counterparties, such as Sanofi Aventis, Novo Nordisk A/S, MedImmune Limited, Bpifrance Participations, SICAV and mutual funds, and different categories of shareholders and financing arrangements. These references indicate that Innate Pharma S.A. discloses information about its capital structure, financing agreements, lease obligations, and relationships with institutional and other shareholders in its regulatory reports.
Innate Pharma S.A. also reports on intangible assets in its filings, including licences and intangible assets under development, as well as tangible assets such as land and buildings, laboratory equipment and other equipment, construction in progress, and right-of-use assets. The filings further mention loan agreements and lease financing obligations with various financial institutions and for different types of assets.
Innate Pharma S.A. is associated with the over-the-counter symbol IPHYF for investors who track the company’s stock. While industry and sector classifications are not specified in the provided data, the company’s detailed IFRS-based financial reporting and references to licensing agreements and intangible assets suggest a focus on activities that involve significant intellectual property and long-term development projects, as reflected in its SEC filings.
Frequently Asked Questions
Innate Pharma Marseille investment returns
How much would $1,000 invested in Innate Pharma Marseille be worth today?
If you invested $1,000 in Innate Pharma Marseille (IPHYF) 1 years ago on 2025-09-10, your investment would be worth $1,019 as of 2026-05-27, representing a +1.9% total return, growing at a compounded rate of 2.6% per year (CAGR).
Has Innate Pharma Marseille outperformed the S&P 500?
Comparison data requires at least 10 years of trading history. Use the calculator above to compare IPHYF performance over available time periods.
What is Innate Pharma Marseille's average annual return?
The compound annual growth rate (CAGR) of IPHYF over the past 1 years is 2.6%, growing at a compounded rate each year. Individual years vary significantly — IPHYF's best recent year was 2025 (+22.4%) and worst was 2022 (-24.7%).
Your Privacy is Protected
This calculator sends the symbol, date, and amount you enter to our server so we can fetch historical market data and render the result. We do not save those entries as a portfolio or account, but standard web server logs may still record the page request.
For informational and educational purposes only — not investment advice.
